Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System
Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Trial Moving Towards Next Interim Analysis and Full Enrollment
As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Operations to Achieve Next Interim Read-Out and Fund Current RenovoCath Commercialization Efforts
LOS ALTOS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, today announced its financial results and operational highlights for the third quarter ended September 30, 2024.
The Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial is being conducted at renowned clinical oncology sites, showcasing the potential of the RenovoCath Delivery System in the treatment of cancer. With the trial moving towards the next interim analysis and full enrollment, the future looks promising for the commercialization of this innovative technology.
With $9.6 million in cash on hand, RenovoRx is well-positioned to fund operations for achieving the next interim read-out and supporting the current commercialization efforts of RenovoCath. The FDA clearance of this delivery system opens up significant revenue potential in both direct sales and through commercial partner channels.
How This Will Effect Me
For individuals battling cancer, the RenovoCath Delivery System represents a beacon of hope. Its targeted drug-delivery platform holds the promise of more effective and less invasive treatments, potentially improving outcomes and quality of life for cancer patients like me.
How This Will Effect the World
The introduction of the RenovoCath Delivery System into the oncology market has the potential to revolutionize cancer treatment on a global scale. By offering a novel approach to targeted therapy delivery, this technology could lead to advancements in the way we combat cancer, ultimately impacting the lives of millions worldwide.
Conclusion
RenovoRx’s progress in the development and commercialization of the RenovoCath Delivery System marks a significant milestone in the fight against cancer. With ongoing clinical trials and financial stability, the Company is poised to make a lasting impact on both individuals and the global oncology landscape.
